ECB’s Nagel: No clear signs that inflation has fed through to price and wage setting
European Central Bank (ECB) policymaker and Bundesbank President Joachim Nagel said in a speech in Sorrento, Italy during the European trading session on Monday that the impact of energy shock-driven inflation has yet not fed into wage growth.
Comments
Longer-term market-based and expert expectations remain consistent with the Eurosystem’s 2% inflation target.
Upward risks dominate the inflation outlook; uncertainty calls for flexibility, not inaction.
Gas prices are especially vulnerable because storage levels are low.
Europe may need to buy substantially higher volumes during the winter.
The destruction of refining capacity is driving up prices for refined petroleum products significantly.
Drought, wildfires and fertiliser shortages also pose risks to food prices.
This was increasing the relative attractiveness of bonds among reserve asset managers.
The case for diversification into gold remains significant given continued geopolitical stress and the credit risk associated with high debt levels.
Market reaction
No immediate impact on the Euro (EUR) from ECB Nagel's comments. At press time, EUR/USD is down 0.3% to near 1.1215 even after recovering a majority of its early losses.
Nagel flags inflation risks, keeps Euro bulls
ECB’s Nagel delivers a stronger-than-usual signal, with a 7.2/10 FXS Speechtracker score versus a 6.6/10 historic average, pointing to a modest hawkish shift. The emphasis that “upward risks dominate the inflation outlook” suggests reluctance to ease policy quickly, which tends to underpin the Euro as markets reassess the path of future rate cuts.
Nagel’s call that “uncertainty calls for flexibility, not inaction” reinforces a bias toward keeping options open for further tightening if needed, rather than committing to a dovish stance. At the same time, noting “no clear signs that inflation has fed through to price and wage setting” tempers the hawkish tone, but overall the balance of risks still leans toward supporting the Euro on expectations of a more persistent anti-inflation stance.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-Alector stock surges after agreement with Genentech on an experimental Parkinson's disease drug
October 5 - The stock price of pharmaceutical company Alector (ALEC.O) surged by 44.20% in pre-market trading, reaching $2.61. The company has entered into a global licensing agreement with Genentech for AL050, an experimental drug developed by ALEC for the treatment of Parkinson's disease. ALEC has granted Genentech the exclusive worldwide rights to develop and commercialize AL050. According to ALEC, the agreement will bring an upfront payment of $100 million and may result in milestone payments of up to $1.17 billion by 2029. The company retains ownership of its ABC technology platform for developing therapies for neurodegenerative diseases, as well as all rights to use the platform in its research and development pipeline. As of the close of the previous trading day, ALEC's stock price had risen by 16.03%. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Due to possible errors in automation or lack of context, Reuters does not guarantee the accuracy of the automated translation, which is provided solely for the convenience of readers. Reuters assumes no responsibility for any damage or loss caused by the use of the automated translation.)
BUZZ - Weakening demand causes Align stock to decline; brokers downgrade rating to "market perform"
October 5 - ** Align Technology (ALGN.O) shares fell 3% in pre-market trading to $139.45 ** Brokerage Evercore ISI downgraded ALGN's rating from "Outperform" to "In Line with the Market" ** The firm cited a "weakening consumer environment," a "sharp slowdown" in September demand indicators, and the potential negative impact of China's volume-based procurement (VBP) in 2027, leading it to adopt a more cautious outlook on Align’s earnings prospects ** VBP (volume-based procurement) is a bulk procurement initiative at the national level in China ** Evercore added that the dental market "has weakened significantly in the third quarter," noting declines in both consumer confidence and expectations ** Deterioration in consumer conditions may have started to affect demand for Invisalign, with Evercore ISI stating that the worsening seen in September "increased the risk that deteriorating consumer conditions may begin to be reflected in Invisalign demand" ** Invisalign is Align’s core business and is projected to contribute approximately $3.2 billions to the company’s total revenue of $4 billions in 2025 ** The broker said early signs of profitability improvement at Align are "beginning to show," but a weak consumer environment and potential VBP headwinds make the process "more challenging" ** As of the previous trading day's close, the stock had declined by about 8% year-to-date.
BUZZ - Insmed shares fall as CFO Sara Bonstein resigns
October 5 - ** Shares of pharmaceutical company Insmed (INSM.O) fell more than 3% in pre-market trading to $107.59. ** Sara Bonstein will resign from her position as Chief Financial Officer, effective October 30. ** Sara will stay on until the end of this month to ensure a smooth transition during the company's release of its Q3 financial results on October 29. ** Before joining Insmed, Sara served as Chief Financial Officer at OncoSec Medical. ** The company reaffirmed its fiscal 2026 performance guidance and has begun the search for the next Chief Financial Officer. ** All 25 brokerages covering the stock remain bullish; the median target price is compiled by LSEG data. ** As of the close of the previous trading day, the stock was down 36.15% year-to-date. (To assist non-English speakers, Reuters automatically translates its reports into several other languages. Because automated translations may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of the translated text and provides automated translation solely for reader convenience. Reuters accepts no liability for any damage or losses caused by the use of automated translation functionality.)
Gilat Satellite Networks' Peruvian Unit Wins $28 Million Contract to Upgrade Broadband Connectivity
07:46 AM EDT, 10/05/2026 (MT Newswires) -- Gilat Satellite Networks (GILT) said Monday that its Peruvian unit has signed a $28 million contract with Pronatel to upgrade broadband connectivity across the country's Ica region. Pronatel is Peru's national telecommunications program, Gilat said. Construction is expected to be completed by mid-2027, followed by a seven-year operational phase, the company said. Gilat said the upgraded network will deliver faster internet speeds to public institutions across the Ica region.
Crypto prices
More
